journal article·2021-10

Lactobacillus cell‐free supernatant as a novel bioagent and biosurfactant against Pseudomonas aeruginosa in the prevention and treatment of orthopedic implant infection

Augustina Jeyanathan, Rita Ramalhete, Gordon Blunn, Hannah Gibbs, Cyrus Anthony Pumilia, Teerin Meckmongkol, John Lovejoy, Melanie J. Coathup

Publisher page

Abstract

Abstract The hypothesis was that probiotic Lactobacillus species (spp.) or their cell‐free supernatant (CFS) are effective in inhibiting (a) planktonic growth of Pseudomonas aeruginosa (PA), (b) its adhesion to a Ti6Al4V‐alloy surface, and (c) in dispersing biofilm once formed. (a) A planktonic co‐culture containing PA(104 colony‐forming unit [CFU]/ml) was combined with either Lactobacillus acidophilus, Lactobacillus plantarum (LP), or Lactobacillus fermentum (LF) at a suspension of 104 (1:1) or 108 CFU/ml (1:2). Lactobacillus and PA CFUs were then quantified. (b) Ti‐6Al‐4V discs were inoculated with PA followed by supplementation with CFS and adherent PA quantified. (c) Biofilm covered discs were supplemented with Lactobacillus CFS and remaining PA activity quantified. Results showed that whole‐cell cultures were ineffective in preventing PA growth; however, the addition of CFS resulted in a 99.99 ± 0.003% reduction in adherent PA in all Lactobacillus groups (p < .05 in all groups) with no viable PA growth measured in the LF and LP groups. Following PA biofilm formation, CFS resulted in a significant reduction in PA activity in all Lactobacillus groups (p ≤ .05 in all groups) with a 29.75 ± 15.98% increase measured in control samples. Supplementation with CFS demonstrated antiadhesive, antibiofilm, and toxic properties to PA.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Orthopedic Infections and Treatments · Bacterial biofilms and quorum sensing · Orthopaedic implants and arthroplasty

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Orthopaedics and Musculoskeletal Science, Division of Surgery and Interventional Science, Royal National Orthopaedic Hospital University College London Stanmore UK

School of Pharmacy and Biomedical Sciences University of Portsmouth Portsmouth UK

Biionix (Bionic Materials, Implants & Interfaces) Cluster, Department of Internal Medicine, College of Medicine, University of Central Florida Orlando Florida USA

Department of General Surgery, Nemours Children's Hospital Orlando Florida USA

Department of Orthopaedics, Sports Medicine and Physical Medicine and Rehabilitation, Nemours Children's Hospital Orlando Florida USA

References (84)

Show source-provided references
1. 10.2106/JBJS.L.0078910.2106/JBJS.L.00789 ↗
2. 10.1111/joim.1223310.1111/joim.12233 ↗
3. 10.2106/00004623-198567020-0001410.2106/00004623-198567020-00014 ↗
4. 10.1111/j.1469-0691.2012.04002.x10.1111/j.1469-0691.2012.04002.x ↗
5. 10.1128/JB.01252-1210.1128/JB.01252-12 ↗
6. 10.1111/joim.1200410.1111/joim.12004 ↗
7. 10.4103/0974-777X.10389610.4103/0974-777X.103896 ↗
8. 10.1002/jbm.b.3197910.1002/jbm.b.31979 ↗
9. 10.1302/2058-5241.1.00003710.1302/2058-5241.1.000037 ↗
10. 10.1086/50753910.1086/507539 ↗
11. Epidemiology of infections associated with combat‐related injuries in Iraq and Afghanistan
12. 10.1097/TA.0b013e318163c40b10.1097/TA.0b013e318163c40b ↗
13. Infection‐associated clinical outcomes in hospitalized medical evacuees after traumatic injury: trauma infectious disease outcome study
14. 10.7150/jbji.1572210.7150/jbji.15722 ↗
15. 10.1016/j.ijid.2010.05.01410.1016/j.ijid.2010.05.014 ↗
16. 10.1016/j.arth.2017.03.06610.1016/j.arth.2017.03.066 ↗
17. 10.2106/00004623-200508000-0001210.2106/00004623-200508000-00012 ↗
18. 10.2217/fmb.14.6410.2217/fmb.14.64 ↗
19. 10.3109/17453674.2010.54802510.3109/17453674.2010.548025 ↗
20. 10.1016/j.otsr.2018.03.01710.1016/j.otsr.2018.03.017 ↗
21. 10.1016/j.jhin.2017.03.00410.1016/j.jhin.2017.03.004 ↗
22. 10.1302/0301-620X.95B1.2983510.1302/0301-620X.95B1.29835 ↗
23. 10.1053/jhin.2000.088110.1053/jhin.2000.0881 ↗
24. 10.1007/s11999-010-1679-810.1007/s11999-010-1679-8 ↗
25. 10.5301/HIP.2012.956610.5301/HIP.2012.9566 ↗
26. 10.1093/jac/dkp10710.1093/jac/dkp107 ↗
27. 10.1016/j.ijantimicag.2018.10.01810.1016/j.ijantimicag.2018.10.018 ↗
28. 10.1111/j.1532-5415.2012.03980.x10.1111/j.1532-5415.2012.03980.x ↗
29. 10.1038/ijos.2014.5210.1038/ijos.2014.52 ↗
30. 10.1080/00365521.1997.1172070810.1080/00365521.1997.11720708 ↗
31. 10.1016/j.ijantimicag.2013.08.00310.1016/j.ijantimicag.2013.08.003 ↗
32. 10.1186/1471-2180-14-10710.1186/1471-2180-14-107 ↗
33. 10.1128/IAI.71.1.428-436.200310.1128/IAI.71.1.428-436.2003 ↗
34. 10.1016/j.vetmic.2009.09.00310.1016/j.vetmic.2009.09.003 ↗
35. Antibacterial effects of bacteriocins isolated from Lactobacillus rhamnosus (ATCC 53103) in a rabbit model of knee implant infection
36. 10.1016/S0168-1605(02)00022-310.1016/S0168-1605(02)00022-3 ↗
37. 10.1007/s10103-017-2394-410.1007/s10103-017-2394-4 ↗
38. 10.1302/2046-3758.912.BJR-2020-0157.R110.1302/2046-3758.912.BJR-2020-0157.R1 ↗
39. 10.1590/S1806-8324200900030000610.1590/S1806-83242009000300006 ↗
40. 10.1128/AEM.66.5.2001-2005.200010.1128/AEM.66.5.2001-2005.2000 ↗
41. 10.1016/S0140-6736(68)90004-410.1016/S0140-6736(68)90004-4 ↗
42. 10.1111/j.1469-0691.2005.01142.x10.1111/j.1469-0691.2005.01142.x ↗
43. 10.1159/00032851210.1159/000328512 ↗
44. Antimicrobial activity of different Lactobacillus species against multi‐ drug resistant clinical isolates of Pseudomonas aeruginosa
45. 10.1016/j.jpha.2015.11.00510.1016/j.jpha.2015.11.005 ↗
46. 10.1093/jac/dkl39310.1093/jac/dkl393 ↗
47. 10.1016/j.idc.2009.06.00810.1016/j.idc.2009.06.008 ↗
48. 10.1128/MMBR.00017-0810.1128/MMBR.00017-08 ↗
49. 10.1186/s40168-016-0155-410.1186/s40168-016-0155-4 ↗
50. 10.1155/2014/92726810.1155/2014/927268 ↗
51. 10.1016/j.foodcont.2006.02.00210.1016/j.foodcont.2006.02.002 ↗
52. 10.1007/978-1-4419-5979-9_910.1007/978-1-4419-5979-9_9 ↗
53. 10.1016/j.colsurfb.2009.11.00810.1016/j.colsurfb.2009.11.008 ↗
54. 10.1128/CDLI.8.2.293-296.200110.1128/CDLI.8.2.293-296.2001 ↗
55. 10.1073/pnas.141571211110.1073/pnas.1415712111 ↗
56. 10.1128/AEM.63.10.3810-3817.199710.1128/AEM.63.10.3810-3817.1997 ↗
57. 10.1002/jobm.20160014310.1002/jobm.201600143 ↗
58. 10.1016/S0090-4295(97)00065-410.1016/S0090-4295(97)00065-4 ↗
59. 10.1111/j.1574-6968.2000.tb09282.x10.1111/j.1574-6968.2000.tb09282.x ↗
60. 10.1099/jmm.0.00022610.1099/jmm.0.000226 ↗
61. 10.1128/AEM.70.7.4408-4410.200410.1128/AEM.70.7.4408-4410.2004 ↗
62. 10.1016/j.micpath.2018.11.03910.1016/j.micpath.2018.11.039 ↗
63. 10.1007/BF0156983210.1007/BF01569832 ↗
64. 10.1016/j.ijbiomac.2013.11.03110.1016/j.ijbiomac.2013.11.031 ↗
65. 10.1016/j.bbrc.2008.12.05310.1016/j.bbrc.2008.12.053 ↗
66. 10.1016/j.carbpol.2010.01.00510.1016/j.carbpol.2010.01.005 ↗
67. 10.1016/j.colsurfb.2011.03.01610.1016/j.colsurfb.2011.03.016 ↗
68. 10.1186/1471-2180-14-19710.1186/1471-2180-14-197 ↗
69. Bacteria against bacteria: anti‐biofilm activity of a selected and patented bacterial compound and its potential role in biofilm‐associated infections
70. 10.1128/AAC.00888-1310.1128/AAC.00888-13 ↗
71. 10.1111/jcmm.1349610.1111/jcmm.13496 ↗
72. 10.1002/jbm.a.3453610.1002/jbm.a.34536 ↗
73. 10.1089/ten.2006.12.161710.1089/ten.2006.12.1617 ↗
74. 10.1089/ten.tea.2008.067610.1089/ten.tea.2008.0676 ↗
75. 10.4076/1752-1947-3-744110.4076/1752-1947-3-7441 ↗
76. 10.3928/01477447-20131219-2210.3928/01477447-20131219-22 ↗
77. 10.1186/s12879-016-1980-610.1186/s12879-016-1980-6 ↗
78. 10.1007/s12602-017-9267-910.1007/s12602-017-9267-9 ↗
79. 10.1128/AEM.37.2.261-265.197910.1128/AEM.37.2.261-265.1979 ↗
80. 10.1139/m71-16010.1139/m71-160 ↗
81. 10.1099/13500872-142-11-319510.1099/13500872-142-11-3195 ↗
82. 10.1111/j.1472-765X.1995.tb01081.x10.1111/j.1472-765X.1995.tb01081.x ↗
83. 10.1128/AAC.39.11.242310.1128/AAC.39.11.2423 ↗
84. 10.1093/jac/dku24710.1093/jac/dku247 ↗